Patents by Inventor Chu-Chung Lin

Chu-Chung Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230012560
    Abstract: A compound of Formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof: (I), in which Ra, Rb, Rc, Rd, X1, X2, R1-R4, W, Z, and L are defined as in the SUMMARY section. Further disclosed are a method of using the above-described compound, salt, stereoisomer, solvate, or prodrug for treating HBV infection and a pharmaceutical composition containing same.
    Type: Application
    Filed: September 4, 2020
    Publication date: January 19, 2023
    Applicant: TAIGEN BIOTECHNOLOGY CO., LTD.
    Inventors: Chih-Ming Chen, Chu-Chung Lin, Chang-Pin Huang, Chiayn Chiang
  • Publication number: 20220249395
    Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C?O)-alkyl, —(C?O)-aryl, —(C?O)-alkyl-aryl, —(C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, O2CH3, —(C?O)—CH3 or (C?O)—NH2.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 11, 2022
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kuo-Kuei HUANG, I-Hong PAN, Shu-Fang WEN, Meng-Nan LIN, I-Huang LU, Zong-Keng KUO, Chu-Hsun LU, Tze-Chung LEE, Ya-Yan YANG, Jia-Horng LIAW, Pei-Hsin LIN
  • Patent number: 11400054
    Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C?O)-alkyl, —(C?O)-aryl, —(C?O)-alkyl-aryl, —(C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, —SO2CH3, —(C?O)—CH3 or —(C?O)—NH2.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 2, 2022
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kuo-Kuei Huang, I-Hong Pan, Shu-Fang Wen, Meng-Nan Lin, I-Huang Lu, Zong-Keng Kuo, Chu-Hsun Lu, Tze-Chung Lee, Ya-Yan Yang, Jia-Horng Liaw, Pei-Hsin Lin
  • Patent number: 10596171
    Abstract: Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5?R6? or NR7?; each of R1, R2, R2?, R3, R3?, R4, R5, R5?, R6, R6?, R7, and R7?, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5? and R6?, or R5 and R5?, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 24, 2020
    Assignee: TaiGen Biotechnology Co., Ltd.
    Inventors: Chu-Chung Lin, Hung-Chuan Chen, Chiayn Chiang, Chi-Feng Yen, Ming-Chu Hsu
  • Patent number: 10377714
    Abstract: A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which R1 is C1-C5 alkyl or C3-C5 cycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: August 13, 2019
    Assignee: TaiGen Biotechnology Co., Ltd.
    Inventors: Shan-Yen Chou, Wen-Chang Chen, Chi-Feng Yen, Han-Pei Hsu, Ming-Chu Hsu, Chu-Chung Lin
  • Publication number: 20190224198
    Abstract: Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5?R6? or NR7?; each of R1, R2, R2?, R3, R3?, R4, R5, R5?, R6, R6?, R7, and R7?, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5? and R6?, or R5 and R5?, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Chu-Chung Lin, Hung-Chuan Chen, Chiayn Chiang, Chi-Feng Yen, Ming-Chu Hsu
  • Publication number: 20190047956
    Abstract: A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which R1 is C1-C5 alkyl or C3-C5 cycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.
    Type: Application
    Filed: August 11, 2017
    Publication date: February 14, 2019
    Inventors: Shan-Yen Chou, Wen-Chang Chen, Chi-Feng Yen, Han-Pei Hsu, Ming-Chu Hsu, Chu-Chung Lin
  • Patent number: 10004719
    Abstract: A spray-dried solid dispersion containing a pharmaceutical compound of formula (I) shown below and a pharmaceutically acceptable polymer, in which the pharmaceutical compound is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing such a solid dispersion and using it for treating hepatitis C virus infection and a pharmaceutical formulation containing same.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 26, 2018
    Assignee: TaiGen Biotechnology Co., Ltd.
    Inventors: Ming-Chu Hsu, Chu-Chung Lin, Chi-Hsin Richard King
  • Patent number: 8389560
    Abstract: This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: March 5, 2013
    Assignee: TaiGen Biotechnology Co., Ltd.
    Inventors: Chen-Fu Liu, Kuang-Yuan Lee, Pei-Chin Cheng, Yo-Chin Liu, Pin Lo, Kuo-Feng Tseng, Chih-Ming Chen, Chi-Hsin Richard King, Chu-Chung Lin
  • Publication number: 20110065737
    Abstract: This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.
    Type: Application
    Filed: September 15, 2009
    Publication date: March 17, 2011
    Applicant: TaiGen Biotechnology Co., Ltd.
    Inventors: Chen-Fu Liu, Kuang-Yuan Lee, Pei-Chin Cheng, Yo-Chin Liu, Pin Lo, Kuo-Feng Tseng, Chih-Ming Chen, Chi-Hsin Richard King, Chu-Chung Lin
  • Patent number: 7662834
    Abstract: This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: wherein R1, R2, R3, R4, and n are defined herein.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: February 16, 2010
    Assignee: National Health Research Institutes
    Inventors: Chiung-Tong Chen, Shu-Jen Chen, Ming-Chu Hsu, Der-Ren Hwang, Wen-Tai Li, Chu-Chung Lin
  • Publication number: 20090286814
    Abstract: This invention relates to macrocyclic compounds of formula (I) or (II) shown in the specification. These compounds can be used to treat hepatitis C virus infection.
    Type: Application
    Filed: November 4, 2008
    Publication date: November 19, 2009
    Applicant: TaiGen Biotechnology Co., Ltd.
    Inventors: Chu-chung Lin, Kuang-Yuan Lee, Yo-chin Liu, Pin Lo, Rong-Jiunn Chen, Chen-Fu Liu, Chih-Ming Chen, Chi-Hsin Richard King
  • Patent number: 7569596
    Abstract: The invention relates to novel imidazolamino compounds. Also disclosed are methods of treating cancer by using one of these compounds and pharmaceutical compositions containing one of these compounds.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: August 4, 2009
    Assignee: National Health Research Institutes
    Inventors: Chiung-Tong Chen, Wen-Tai Li, Der-Ren Hwang, Chu-Chung Lin
  • Publication number: 20090111757
    Abstract: Compounds of formula (I): in which R1, R2, R3 R4, and R5, U, X, Y, and Z are as defined herein. Also disclosed is use of these compounds, alone or in combination with other active agents, to treat hepatitis C virus infection.
    Type: Application
    Filed: October 20, 2008
    Publication date: April 30, 2009
    Applicant: TaiGen Biotechnology Co., Ltd.
    Inventors: Chu-Chung Lin, Kuang-Yuan Lee, Chen-Fu Liu, Pin Lo, Yo-Chin Liu, Yueh-chiang Han, Chi-Hsin Richard King
  • Patent number: 7462723
    Abstract: The invention relates to novel imidazolamino compounds. Also disclosed are methods of treating cancer by using one of these compounds and pharmaceutical compositions containing one of these compounds.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: December 9, 2008
    Assignee: National Health Research Institutes
    Inventors: Chiung-Tong Chen, Wen-Tai Li, Der-Ren Hwang, Chu-Chung Lin
  • Publication number: 20080242701
    Abstract: This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: wherein R1, R2, R3, R4, and n are defined herein.
    Type: Application
    Filed: June 3, 2008
    Publication date: October 2, 2008
    Applicant: National Health Research Institutes
    Inventors: Chiung-Tong Chen, Shu-Jen Chen, Ming-Chu Hsu, Der-Ren Hwang, Wen-Tai Li, Chu-Chung Lin
  • Patent number: 7396838
    Abstract: A method of treating cancer including administering to a subject in need thereof an effective amount of a compound of the formula 1: wherein R1, R2, R3, R4, and n are as defined herein.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: July 8, 2008
    Assignee: National Health Research Institutes
    Inventors: Chiung-Tong Chen, Shu-Jen Chen, Ming-Chu Hsu, Der-Ren Hwang, Wen-Tai Li, Chu-Chung Lin
  • Patent number: 7378524
    Abstract: This invention relates to treating inflammatory and immune diseases with certain aminoquinoline compounds that bind to CXCR3 receptors. The aminoquinoline compounds are covered by the formula (I) shown below. Each variable is defined in the specification.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: May 27, 2008
    Assignee: Taigen Biotechnology Co., Ltd.
    Inventors: Chu-Chung Lin, Jen-Fuh Liu, Chih-Wei Chang, Shu-Jen Chen, Yibin Xiang, Pei-Chin Cheng, Jiing-Jyh Jan
  • Publication number: 20080108632
    Abstract: This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection.
    Type: Application
    Filed: November 2, 2007
    Publication date: May 8, 2008
    Applicant: TaiGen Biotechnology Co., Ltd.
    Inventors: Chu-chung Lin, Pei-chin Cheng, Yo-chin Liu, Chen-fu Liu, Chi-Hsin Richard King
  • Patent number: 7183413
    Abstract: This invention relates to treating inflammatory and immune diseases with certain aminoquinoline compounds that bind to CXCR3 receptors. The aminoquinoline compounds are covered by the formula (I) shown below. Each variable is defined in the specification.
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: February 27, 2007
    Assignee: Taigen Biotechnology
    Inventors: Chu-Chung Lin, Jen-Fuh Liu, Chih-Wei Chang, Shu-Jen Chen, Yibin Xiang, Pei-Chin Cheng, Jiing-Jyh Jan